Acute kidney injury – A frequent and serious complication after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction

Autoři: Abdellatif El-Ahmadi aff001;  Mujahed Sebastian Abassi aff001;  Hedvig Bille Andersson aff001;  Thomas Engstrøm aff001;  Peter Clemmensen aff002;  Steffen Helqvist aff001;  Erik Jørgensen aff001;  Henning Kelbæk aff004;  Frants Pedersen aff001;  Kari Saunamäki aff001;  Jacob Lønborg aff001;  Lene Holmvang aff001
Působiště autorů: Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Denmark aff001;  Department of General and Intervention Cardiology, University Heart Center, Hamburg-Eppendorf, Germany aff002;  Department of Medicine, Division of Cardiology, Nykoebing-Falster Hospital, University of Southern Denmark, Odense, Denmark aff003;  Department of Cardiology, Zealand University Hospital, Denmark aff004
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article



The aim of the study was to investigate the incidence, risk factors and long-term prognosis of acute kidney injury (AKI) in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (primary PCI).


A large-scale, retrospective cohort study based on procedure-related variables, biochemical and mortality data collected between 2009 and 2014 at Rigshospitalet, Copenhagen, Denmark. AKI was defined as an increase in serum creatinine of 25% during the first 72 hours after the index procedure.


A total of 4239 patients were treated with primary PCI of whom 4002 had available creatinine measurements allowing for assessment of AKI and inclusion in this study. The mean creatinine value upon presentation for all patients was 84 μmol/l (standard deviation (SD) ±40) and 97 μmol/l (SD ±53) at peak. AKI occurred in a total of 765 (19.1%) patients. Independent risk factors for the occurrence of AKI were age, time from symptom onset to procedure, peak value of troponin-T, female sex and the contrast volume to eGFR ratio. In a multivariable adjusted analysis AKI was independently associated with a higher mortality rate at 5 years follow-up (hazard ratio 1.39 [95%-confidence interval 1.03–1.88]).


In STEMI patients treated with primary PCI one in five experiences acute kidney injury, which was associated with a substantial increase in both short- and long-term mortality.

Klíčová slova:

Cardiac arrest – Coronary angioplasty – Coronary artery bypass grafting – Creatinine – Death rates – Kidneys – Medical risk factors – Myocardial infarction


1. Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger M a, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J [Internet]. 2012 Oct [cited 2014 Jul 9];33(20):2569–619. Available from: doi: 10.1093/eurheartj/ehs215 22922416

2. Puymirat E, Simon T, Cayla G, Yves C. Acute Myocardial Infarction. Circulation. 2017;136:00.

3. Tsai TT, Patel UD, Chang TI, Kennedy KF, Masoudi F a, Matheny ME, et al. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. JACC Cardiovasc Interv [Internet]. 2014 Jan [cited 2015 Jan 7];7(1):1–9. Available from: doi: 10.1016/j.jcin.2013.06.016 24456715

4. Morcos S, Thomsen H, Webb J. Contrast-media-induced nephrotoxicity: a consensus report. Eur Radiol [Internet]. Springer-Verlag; 1999 [cited 2015 Jan 5];9(8):1602–13. Available from: doi: 10.1007/s003300050894 10525875

5. Silvain J, Collet J-P, Montalescot G. Contrast-induced nephropathy: the sin of primary percutaneous coronary intervention? Eur Heart J [Internet]. 2014 Jun 14 [cited 2014 Jul 12];35(23):1504–6. Available from: doi: 10.1093/eurheartj/ehu126 24722806

6. Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, Marana I, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol [Internet]. 2004 Nov 2 [cited 2014 Sep 4];44(9):1780–5. Available from: doi: 10.1016/j.jacc.2004.07.043 15519007

7. Rihal CS. Incidence and Prognostic Importance of Acute Renal Failure After Percutaneous Coronary Intervention. Circulation [Internet]. 2002 Apr 22 [cited 2014 Aug 27];105(19):2259–64. Available from: 12010907

8. Narula A, Mehran R, Weisz G, Dangas GD, Yu J, Généreux P, et al. Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy. Eur Heart J [Internet]. 2014 Jun 14 [cited 2014 Jul 14];35(23):1533–40. Available from: doi: 10.1093/eurheartj/ehu063 24603308

9. Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, Lansky AJ, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation [Internet]. 2003 Dec 2 [cited 2014 Sep 7];108(22):2769–75. Available from: doi: 10.1161/01.CIR.0000103623.63687.21 14638545

10. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation [Internet]. 2006 Apr 11 [cited 2014 Sep 5];113(14):1799–806. Available from: doi: 10.1161/CIRCULATIONAHA.105.595090 16606801

11. Fliser D, Laville M, Van Biesen W. A European Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant [Internet]. 2012 Oct 8; 0:1–10.

12. Rudnick M, Feldman H. Contrast-induced nephropathy: what are the true clinical consequences? Clin J Am Soc Nephrol [Internet]. 2008 Jan [cited 2014 Sep 8];3(1):263–72. Available from: doi: 10.2215/CJN.03690907 18178787

13. Levy E, Viscoli C, Horwitz R. The effect of acute renal failure on mortality: A cohort analysis. JAMA [Internet]. 1996 May 15;275(19):1489–94. Available from: 8622223

14. Thomsen HS, Morcos SK, Barrett BJ. Contrast-induced nephropathy: the wheel has turned 360 degrees. Acta Radiol [Internet]. 2008 Jul [cited 2014 Jul 12];49(6):646–57. Available from: doi: 10.1080/02841850801995413 18568557

15. Thiele H, Akin I, Sandri M, Fuernau G, Waha S De, Saraei RM, et al. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med. 2017;377(25):2419–32. doi: 10.1056/NEJMoa1710261 29083953

16. Barrett B. Contrast nephrotoxicity. J Am Soc Nephrol. 1994;5:125–37. 7993992

17. Celik O, Ozturk D, Akin F, Ayca B, Yalaki AA, Erturk M, et al. Association Between Contrast Media Volume-Glomerular Filtration Rate Ratio and Contrast-Induced Acute Kidney Injury After Primary Percutaneous Coronary Intervention. Angiology. 2014 Jul 8;

18. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal Considerations in Angiotensin Converting Enzyme Inhibitor Therapy. Circulation. 2001;104:1985–91. doi: 10.1161/hc4101.096153 11602506

19. Shacham Y, Leshem-Rubinow E, Gal-Oz A. Acute Cardio-Renal Syndrome as a Cause for Renal Deterioration Among Myocardial Infarction Patients Treated With Primary Percutaneous Intervention. Can J Cardiol. 2015;31(10):1240–44. doi: 10.1016/j.cjca.2015.03.031 26163472

20. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol [Internet]. 2004 Oct 6 [cited 2014 Dec 10];44(7):1393–9. Available from: doi: 10.1016/j.jacc.2004.06.068 15464318

21. Rudnick MLR, Goldfarb S, Wexler L. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: A randomized trial. Kidney Int. 1995;47:254–61. doi: 10.1038/ki.1995.32 7731155

22. Shacham Y, Gal-Oz A, Leshem-Rubinov E. Admission Glucose Levels and the Risk of Acute Kidney Injury in Nondiabetic ST Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention. Cardiorenal Med. 2015;5:191–8. doi: 10.1159/000430472 26195971

23. Stone GW, McCullough PA, Tumlin JA, Lepor NE, Madyoon H, Murray P, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy. JAMA J Am Med Assoc. 2003;290(17):2284–91.

24. Merten GJ, Burgess WP, Gray L V, Holleman JH, Roush TS, Kowalchuk GJ, et al. Prevention of Contrast-Induced Nephropathy. JAMA J Am Med Assoc. 2004;291(19):2328–34.

25. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: eff ectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med. 2008;148:284–94. doi: 10.7326/0003-4819-148-4-200802190-00007 18283206

26. Weisbord SD, Gallagher M, Conner TA, Chertow GM, Bhatt DL, Shunk K, et al. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. N Engl J Med. 2017;1–12.

27. Mueller C. Prevention of contrast media-associated nephropathy. Arch Intern Med. 2002;162:329–36. doi: 10.1001/archinte.162.3.329 11822926

28. Schweiger MJ, Chambers CE, Davidson CJ, Zhang S, Blankenship J, Bhalla NP, et al. Prevention of contrast induced nephropathy: Recommendations for the high risk patient undergoing cardiovascular procedures. Vol. 69, Catheterization and Cardiovascular Interventions. 2007. p. 135–40. doi: 10.1002/ccd.20964 17139671

29. Flaherty M, Pant S, Patel S, Al E. Hemodynamic Support with a Micro-Axial Percutaneous Left Ventricular Assist Device (Impella®) Protects Against Acute Kidney Injury in Patients Undergoing High-Risk Percutaneous Coronary Intervention. Circ Res [Internet]. 2018;123(2). Available from:

30. Mehran Roxana, Weisbord SD et al. Contrast- Associated Acute Kidney Injury. N Engl J Med May 2019: 380:22. p 2146–2155.

Článek vyšel v časopise


2019 Číslo 12
Nejčtenější tento týden